// App-Quantinova.ai

: Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Researchers

Presenter

  • Jaimal Kothari

Principal Investigators

  • Toby A. Eyre

  • Ali Rismani

  • Helen McCarthy

  • Angela Collins

  • David John Lewis

  • Suzanne O Arulogun

  • William Wilson

  • Laura Clifton-Hadley

  • Darren Edwards

  • Kushani Ediriwickrema

  • Rebecca Auer

  • Guy Pratt

  • Ruth M. de Tute

  • Roger G Owen

  • Shirley D'Sa

Medical Centers

  • Cancer Research UK & UCL Cancer Trials Centre, University College London, London, United Kingdom

  • HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • University College London Hospital, UCLH Centre for Waldenström and Related Conditions, London, United Kingdom

  • Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom

  • Queen Elizabeth Hospital Birmingham, WMRC, Birmingham, United Kingdom

  • The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • University College London Hospitals NHS Foundation Trust, London, United Kingdom

  • Department of Haematology, Derriford Hospital, Plymouth, United Kingdom

  • Haematology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom

  • Cancer Research UK Clinical Trials Unit, University College London Cancer Trials Centre, London, United Kingdom

  • Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Safety

  • Open Label

  • Single Arm

  • Non Randomized

  • Multinational

  • Multicenteric

  • Tolerability

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved